Physician profile
Pedro Lopez
NPI 1295796472
$17,799.04
in general payments reported to CMS, 2019-2025
41 companies · $3,297 in 2025
The $3,297 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,017 · 2020: $1,878 · 2021: $2,432 · 2022: $2,579 · 2023: $2,821 · 2024: $2,775 · 2025: $3,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,588 · Education: $269 · Consulting Fee: $35.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,588.35 |
| Education | $268.97 |
| Consulting Fee | $35.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,890.48 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $2,712.36 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mallinckrodt Hospital Products INC. | $2,224.64 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,560.01 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $902.86 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $876.48 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $739.38 | 2020-2025 | Glassia |
| Amgen INC. | $529.55 | 2022-2025 | Tezspire |
| Insmed, INC. | $481.14 | 2019-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $418.99 | 2019-2025 | Smartvest |
| Mylan Specialty L.P. | $393.76 | 2019-2024 | Yupelri |
| Genzyme Corporation | $322.80 | 2024-2025 | |
| Pfizer INC. | $301.84 | 2021-2025 | |
| Gilead Sciences, INC. | $229.55 | 2021-2022 | |
| Genentech USA, INC. | $229.15 | 2019-2023 | Xolair |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $225.78 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Astellas Pharma US INC | $203.84 | 2022-2024 | Cresemba |
| Mallinckrodt Enterprises LLC | $195.45 | 2019 | |
| Sunovion Pharmaceuticals INC. | $145.64 | 2019-2020 | |
| Inogen, INC. | $129.64 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Ani Pharmaceuticals, INC. | $120.09 | 2023-2025 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $109.95 | 2020-2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $108.48 | 2019-2020 | |
| Baxter Healthcare | $105.42 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Shire North American Group INC | $84.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Verona Pharma, INC. | $56.72 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $53.55 | 2019 | |
| Portola Pharmaceuticals, LLC | $46.93 | 2019 | |
| Csl Behring | $45.06 | 2023-2025 | Hizentra, Kcentra |
| Pulmonx Corporation | $42.34 | 2020-2022 | |
| Adma Biomanufacturing LLC | $35.91 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $34.34 | 2019-2023 | Opsumit |
| Harmony Biosciences LLC | $30.33 | 2025 | |
| 3b Medical, INC. | $29.82 | 2025 | Luna |
| La Jolla Pharmaceutical Company | $29.09 | 2021 | |
| Chiesi USA, INC. | $20.14 | 2023 | Cleviprex |
| Allergan, INC. | $14.62 | 2019 | |
| Viatris Specialty LLC | $14.19 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $12.97 | 2022 | |
| Vapotherm INC | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.